Avanza Fonder AB Takes $4.85 Million Position in Edwards Lifesciences Co. (NYSE:EW)

Avanza Fonder AB acquired a new position in Edwards Lifesciences Co. (NYSE:EW) during the fourth quarter, HoldingsChannel.com reports. The institutional investor acquired 65,442 shares of the medical research company’s stock, valued at approximately $4,845,000.

A number of other large investors have also modified their holdings of the company. RDA Financial Network increased its position in Edwards Lifesciences by 1.6% in the 4th quarter. RDA Financial Network now owns 33,770 shares of the medical research company’s stock valued at $2,500,000 after acquiring an additional 523 shares during the period. Empirical Asset Management LLC bought a new position in shares of Edwards Lifesciences in the fourth quarter worth $257,000. Central Valley Advisors LLC increased its holdings in shares of Edwards Lifesciences by 13.8% during the fourth quarter. Central Valley Advisors LLC now owns 17,639 shares of the medical research company’s stock valued at $1,306,000 after purchasing an additional 2,145 shares during the period. Gateway Investment Advisers LLC raised its stake in shares of Edwards Lifesciences by 97.8% during the fourth quarter. Gateway Investment Advisers LLC now owns 11,581 shares of the medical research company’s stock valued at $857,000 after purchasing an additional 5,726 shares in the last quarter. Finally, Roble Belko & Company Inc acquired a new stake in Edwards Lifesciences in the fourth quarter worth about $46,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have commented on the stock. Royal Bank of Canada raised their target price on shares of Edwards Lifesciences from $80.00 to $85.00 and gave the company an “outperform” rating in a research note on Thursday, December 5th. Wolfe Research cut Edwards Lifesciences from a “peer perform” rating to an “underperform” rating and set a $60.00 target price on the stock. in a report on Thursday. Robert W. Baird cut their target price on Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating for the company in a research report on Friday, October 25th. Evercore ISI lowered their price target on Edwards Lifesciences from $76.00 to $70.00 and set an “in-line” rating on the stock in a research report on Tuesday, October 1st. Finally, JPMorgan Chase & Co. upped their price objective on Edwards Lifesciences from $72.00 to $78.00 and gave the company a “neutral” rating in a report on Friday, October 25th. One investment analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and eleven have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $78.48.

Edwards Lifesciences Stock Performance

Shares of Edwards Lifesciences stock opened at $69.77 on Friday. The stock has a market cap of $41.15 billion, a PE ratio of 10.07, a price-to-earnings-growth ratio of 3.77 and a beta of 1.11. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $96.12. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. The business has a fifty day simple moving average of $71.99 and a 200-day simple moving average of $71.60.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, meeting the consensus estimate of $0.67. The company had revenue of $1.35 billion for the quarter, compared to analysts’ expectations of $1.57 billion. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The business’s revenue for the quarter was up 8.9% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.59 EPS. On average, sell-side analysts anticipate that Edwards Lifesciences Co. will post 2.56 EPS for the current fiscal year.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of the company’s stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $65.57, for a total value of $327,850.00. Following the transaction, the vice president now directly owns 46,936 shares of the company’s stock, valued at $3,077,593.52. This represents a 9.63 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Larry L. Wood sold 25,000 shares of Edwards Lifesciences stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total value of $1,647,750.00. Following the sale, the insider now owns 198,526 shares of the company’s stock, valued at approximately $13,084,848.66. This represents a 11.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 33,000 shares of company stock worth $2,195,180. 1.27% of the stock is currently owned by company insiders.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.